Research programme: tubulin polymerisation inhibitors - Ipsen

Drug Profile

Research programme: tubulin polymerisation inhibitors - Ipsen

Alternative Names: IRC-083927; STX 140; STX 243; STX 2484; Tetrahydroisoquinoline-based compounds; THIQ-based compounds

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sterix
  • Developer Ipsen
  • Class Antineoplastics; Cyclopentanes; Phenanthrenes
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Microtubule protein inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (PO)
  • 16 Nov 2010 Preclinical development is ongoing in the UK - compound optimisation update presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
  • 09 Sep 2010 Pharmacodynamics and adverse events data from a preclinical trial in Solid tumours presented at the 21st International Symposium on Medicinal Chemistry (ISMC-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top